Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

36
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
Translation01:31

Translation

158.2K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
158.2K
Translation01:31

Translation

19.6K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
19.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Mediterranean journal of rheumatology·2026
Same author

Mediterranean Diet Adherence, Dietary Components, and Vision-Related Quality of Life in Type 2 Diabetes: A Cross-Sectional Study According to Diabetic Retinopathy Status.

Nutrients·2026
Same author

Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study.

Scientific reports·2026
Same author

OUtcome and Clinical Characteristics of Primary Headache in Patients with Sarcoidosis: The OUCH! Study.

Life (Basel, Switzerland)·2026
Same author

Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan<sup>®</sup>: a systematic review and meta-analysis.

Internal and emergency medicine·2026
Same author

Recombinant dimeric PICK1 peptide inhibitors for long-term relief of chronic pain by AAV therapeutics.

Cell reports. Medicine·2026

Related Experiment Video

Updated: Feb 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Differential TBXA2 receptor transcript stability is dependent on the C924T polymorphism.

Vincenzo De Iuliis1, Sebastiano Ursi1, Alfonso Pennelli2

  • 1SS Annunziata University Hospital, Unit of Clinical Molecular Biology and Predictive Medicine, University of Chieti, ASL Lanciano-Vasto-Chieti, Chieti, Italy.

Prostaglandins & Other Lipid Mediators
|July 16, 2017
PubMed
Summary

The TBXA2R TT genotype may protect against atherothrombosis by increasing transcript instability and reducing platelet aggregation, especially in aspirin-treated patients. This finding highlights the post-transcriptional role of the C924T polymorphism in cardiovascular health.

Keywords:
Gene expressionPlatelet aggregationSingle nucleotide polymorphism

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.4K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.6K

Area of Science:

  • Molecular Biology
  • Genetics
  • Cardiovascular Research

Background:

  • Investigated the post-transcriptional role of the C924T polymorphism (rs4523) in the 3' region of the TBXA2R gene.
  • Aimed to better characterize molecular mechanisms involved in processing mutated transcripts.

Purpose of the Study:

  • To analyze the impact of the C924T polymorphism on TBXA2R mRNA stability and receptor expression.
  • To correlate these molecular changes with platelet aggregation and potential atherothrombotic risk.

Main Methods:

  • Dose-response experiments with Actinomycin D on MEG-01 cells to assess cell viability.
  • Quantitative real-time PCR (qRT-PCR) to analyze TBXA2R mRNA stability.
  • Analysis of TBXA2R expression levels and glycosylation in wild type (CC) versus mutant (TT) genotypes.
  • Assessment of platelet aggregation in relation to the C924T polymorphism.

Main Results:

  • Actinomycin D significantly decreased cell viability, with greater impact at higher concentrations and longer treatment durations.
  • TBXA2R mRNA stability was increased for the wild type (C) allele compared to the mutant (T) allele.
  • The wild type (CC) genotype showed higher TBXA2R expression (including glycosylated forms) compared to the mutant (TT) genotype.
  • Reduced platelet aggregation was observed in individuals with the TT genotype, irrespective of the aggregation stimulus.

Conclusions:

  • The TBXA2R TT genotype is associated with increased mRNA instability and reduced platelet aggregation.
  • These findings suggest a potential protective role of the TBXA2R TT genotype against atherothrombosis.
  • This protective effect may be particularly relevant in high-risk, aspirin-treated patients.